PetMed Express Inc. Reports Fiscal Year 2024 Results: Challenges Amidst Growth
PetMed Express Inc. (NASDAQ: PETS), a leading direct-to-consumer pet pharmacy, released its annual report for the fiscal year ended March 31, 2024. The report outlines a complex year marked by a notable acquisition, rising expenses, and a significant shift in financial performance. Here’s an in-depth look at the key highlights from the report.
1. Sales Growth Driven by Acquisition
PetMed Express reported total sales of approximately $281.1 million for the fiscal year 2024, an increase of 9.5% from $256.6 million in 2023. This growth can largely be attributed to incremental sales and membership fees from the acquisition of PetCareRx, which was finalized in April 2023. However, this positive trend was countered by declines in new customer and reorder sales.
Revenue Breakdown by Major Customers
The revenue generated from major customer segments reveals critical insights into PetMed's sales dynamics.
- New Order Sales: $24.3 million
- Reorder Sales: $246.9 million
- Membership Fees: $9.78 million
2. Rising Costs Challenge Profitability
Despite increased sales, the cost of sales also rose by approximately $16.6 million, or 8.9%, reaching $202.4 million. This uptick in costs reflects the company’s broader operational challenges, including increased general and administrative expenses, which surged by 32.4% to $55.2 million. Key contributors to this increase included payroll expenses, professional fees, and overhead costs.
Advertising and Depreciation Expenses
Advertising expenses grew to $24.5 million, an increase of $5.1 million driven by media spending associated with PetCareRx. Additionally, depreciation and amortization expenses jumped to $7.1 million due to new property and equipment additions, alongside $2.0 million in amortization for intangibles acquired from the PetCareRx deal.
3. Significant Drop in Net Income
The company reported a net loss of approximately $7.5 million for fiscal 2024, a stark decline from a net income of $5.1 million in fiscal 2023. This downturn in profitability can be attributed to escalating general and advertising expenses, despite higher gross profit margins.
Income Statement Highlights
| May 2023 | Jun 2024 | |
|---|---|---|
Net Income | 5.14M | -7.46M |
Profit | 5.14M | -7.46M |
Net Income Continuing | 5.14M | -7.46M |
Income Tax Expense | 2.30M | 1.19M |
Pretax Income | 7.44M | -6.27M |
Non-operating Income | 1.39M | 1.88M |
Operating Income | 6.05M | -8.16M |
Revenue | 256.5M | 281.0M |
Costs and Expenses | 250.5M | 289.2M |
Cost of Revenue | 185.8M | 202.4M |
Operating Expenses | 64.68M | 86.81M |
Depreciation, Depletion & Amortization | 3.54M | 7.05M |
Selling, General & Administrative | 61.13M | 79.75M |
- Revenue: $281.0 million
- Costs and Expenses: $289.2 million
- Net Income: $-7.46 million
4. Liquidity and Capital Resources Under Pressure
PetMed Express's working capital decreased significantly from $72.9 million in 2023 to $21.5 million in 2024. This decline resulted from the $36 million spent on acquiring PetCareRx and a decrease in operational income. The company’s cash position also took a hit, with a net change in cash of -$48.79 million driven by substantial investing and financing activities.
Cash Flow Overview
| May 2023 | Jun 2024 | |
|---|---|---|
Net Change in Cash | -6.99M | -48.79M |
Net Cash from Operating Activities | 27.80M | 4.31M |
Operating Profit | 5.14M | -7.46M |
Adjustment to Operating Profit | 22.66M | 11.78M |
Net Cash from Investing Activities | -10.26M | -40.67M |
Business & Interest in Affiliates | 5M | 36.15M |
Productive Assets | 5.26M | 4.51M |
Net Cash from Financing Activities | -24.53M | -12.43M |
Dividends | 24.53M | 12.43M |
- Net Cash from Operating Activities: $4.31 million
- Net Cash from Investing Activities: -$40.67 million
- Net Cash from Financing Activities: -$12.43 million
5. Dividend Suspension and Future Outlook
In light of its financial challenges, PetMed Express's Board of Directors suspended the quarterly dividend indefinitely on February 1, 2024. The decision reflects a strategic shift to prioritize growth initiatives and manage cash flow effectively.
6. Legal Proceedings and Challenges Ahead
PetMed is currently facing various legal challenges, including a lawsuit alleging violations of Pennsylvania's consumer protection laws. The implications of these legal proceedings could further complicate the company's operational landscape.
7. Conclusion
PetMed Express Inc. has encountered a tumultuous year characterized by significant expenses and a sharp decline in net income, overshadowing the positives from its acquisition of PetCareRx. As the company navigates through these challenges, stakeholders will be keenly watching how it adapts to maintain its market position while striving for profitability. The future remains uncertain, but the commitment to growth and operational efficiency will be critical in shaping its trajectory.
